Quality Assurance and Preventing Serious Adverse Events in the Home Hemodialysis Setting

Keigan M. More, Karthik Tennankore

Producción científica: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

3 Citas (Scopus)

Resumen

Patient safety is of the utmost importance in home hemodialysis (HHD). Recognizing that there are risks related to vascular access (both infectious and noninfectious events), dialysis water quality, and procedural-related adverse events (including arteriovenous fistula needle dislodgement or air embolism), there is a need for systematic identification and management. Although adverse events are relatively infrequent in HHD, the potential consequences of these events may include significant morbidity, HHD treatment failure, or death. Therefore, having a systematic framework to review each event, audit and retrain patient technique, disclose and discuss events with patients, home unit staff and device companies (if relevant) and determine preventative measures to avoid future adverse events, is crucial. In this review, we will describe the literature around the types and relative frequency of serious adverse events in the HHD setting and we will outline a quality assurance framework for capturing, managing, and avoiding serious adverse events. Finally, we will describe some of the novel existing approaches to preventing or addressing serious adverse events and critical knowledge gaps that should be evaluated in future study.

Idioma originalEnglish
Páginas (desde-hasta)170-177
Número de páginas8
PublicaciónAdvances in Chronic Kidney Disease
Volumen28
N.º2
DOI
EstadoPublished - mar. 2021

Nota bibliográfica

Funding Information:
Financial Disclosure: The authors declare that they have no relevant financial interests. Support: K.T. has received investigator-initiated grant support from Astellas, Otsuka, and Baxter. He has conducted consulting work/Advisory Board work for Otsuka, Janssen, Baxter, and AstraZeneca. K.M. has no conflicts to declare.

Funding Information:
Support: K.T. has received investigator-initiated grant support from Astellas, Otsuka, and Baxter. He has conducted consulting work/Advisory Board work for Otsuka, Janssen, Baxter, and AstraZeneca. K.M. has no conflicts to declare.

Publisher Copyright:
© 2021 National Kidney Foundation, Inc.

ASJC Scopus Subject Areas

  • Nephrology

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't
  • Review

Huella

Profundice en los temas de investigación de 'Quality Assurance and Preventing Serious Adverse Events in the Home Hemodialysis Setting'. En conjunto forman una huella única.

Citar esto